Focusing on the diabetes as the core therapeutic field,
Wanbang Biopharma has established a core competitive advantage in R&D, production and sales in the field of "Four High One Anti" (hyperglycemia, hypertension, hyperlipidemia, hyperuricemia and anti-tumor).
